217 related articles for article (PubMed ID: 28073004)
1. Epigenetic siRNA and Chemical Screens Identify SETD8 Inhibition as a Therapeutic Strategy for p53 Activation in High-Risk Neuroblastoma.
Veschi V; Liu Z; Voss TC; Ozbun L; Gryder B; Yan C; Hu Y; Ma A; Jin J; Mazur SJ; Lam N; Souza BK; Giannini G; Hager GL; Arrowsmith CH; Khan J; Appella E; Thiele CJ
Cancer Cell; 2017 Jan; 31(1):50-63. PubMed ID: 28073004
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic Modifier SETD8 as a Therapeutic Target for High-Grade Serous Ovarian Cancer.
Wada M; Kukita A; Sone K; Hamamoto R; Kaneko S; Komatsu M; Takahashi Y; Inoue F; Kojima M; Honjoh H; Taguchi A; Kashiyama T; Miyamoto Y; Tanikawa M; Tsuruga T; Mori-Uchino M; Wada-Hiraike O; Osuga Y; Fujii T
Biomolecules; 2020 Dec; 10(12):. PubMed ID: 33339442
[TBL] [Abstract][Full Text] [Related]
3. Histone-lysine methyltransferase EHMT2 is involved in proliferation, apoptosis, cell invasion, and DNA methylation of human neuroblastoma cells.
Lu Z; Tian Y; Salwen HR; Chlenski A; Godley LA; Raj JU; Yang Q
Anticancer Drugs; 2013 Jun; 24(5):484-93. PubMed ID: 23466651
[TBL] [Abstract][Full Text] [Related]
4. The PPARγ-SETD8 axis constitutes an epigenetic, p53-independent checkpoint on p21-mediated cellular senescence.
Shih CT; Chang YF; Chen YT; Ma CP; Chen HW; Yang CC; Lu JC; Tsai YS; Chen HC; Tan BC
Aging Cell; 2017 Aug; 16(4):797-813. PubMed ID: 28514051
[TBL] [Abstract][Full Text] [Related]
5. Targeting the methyltransferase SETD8 impairs tumor cell survival and overcomes drug resistance independently of p53 status in multiple myeloma.
Herviou L; Ovejero S; Izard F; Karmous-Gadacha O; Gourzones C; Bellanger C; De Smedt E; Ma A; Vincent L; Cartron G; Jin J; De Bruyne E; Grimaud C; Julien E; Moreaux J
Clin Epigenetics; 2021 Sep; 13(1):174. PubMed ID: 34530900
[TBL] [Abstract][Full Text] [Related]
6. NSC-87877 inhibits DUSP26 function in neuroblastoma resulting in p53-mediated apoptosis.
Shi Y; Ma IT; Patel RH; Shang X; Chen Z; Zhao Y; Cheng J; Fan Y; Rojas Y; Barbieri E; Chen Z; Yu Y; Jin J; Kim ES; Shohet JM; Vasudevan SA; Yang J
Cell Death Dis; 2015 Aug; 6(8):e1841. PubMed ID: 26247726
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.
Van Maerken T; Ferdinande L; Taildeman J; Lambertz I; Yigit N; Vercruysse L; Rihani A; Michaelis M; Cinatl J; Cuvelier CA; Marine JC; De Paepe A; Bracke M; Speleman F; Vandesompele J
J Natl Cancer Inst; 2009 Nov; 101(22):1562-74. PubMed ID: 19903807
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic Determinants of Erythropoiesis: Role of the Histone Methyltransferase SetD8 in Promoting Erythroid Cell Maturation and Survival.
DeVilbiss AW; Sanalkumar R; Hall BD; Katsumura KR; de Andrade IF; Bresnick EH
Mol Cell Biol; 2015 Jun; 35(12):2073-87. PubMed ID: 25855754
[TBL] [Abstract][Full Text] [Related]
9. Targeted inhibition of the methyltransferase SETD8 synergizes with the Wee1 inhibitor adavosertib in restraining glioblastoma growth.
Della Monica R; Buonaiuto M; Cuomo M; Pagano C; Trio F; Costabile D; de Riso G; Cicala FS; Raia M; Franca RA; Del Basso De Caro M; Sorrentino D; Navarra G; Coppola L; Tripodi L; Pastore L; Hench J; Frank S; Schonauer C; Catapano G; Bifulco M; Chiariotti L; Visconti R
Cell Death Dis; 2023 Sep; 14(9):638. PubMed ID: 37758718
[TBL] [Abstract][Full Text] [Related]
10. Progress in the Development of Lysine Methyltransferase SETD8 Inhibitors.
Milite C; Feoli A; Viviano M; Rescigno D; Mai A; Castellano S; Sbardella G
ChemMedChem; 2016 Aug; 11(16):1680-5. PubMed ID: 27411844
[TBL] [Abstract][Full Text] [Related]
11. The Histone Methyltransferase SETD8 Regulates the Expression of Tumor Suppressor Genes via H4K20 Methylation and the p53 Signaling Pathway in Endometrial Cancer Cells.
Kukita A; Sone K; Kaneko S; Kawakami E; Oki S; Kojima M; Wada M; Toyohara Y; Takahashi Y; Inoue F; Tanimoto S; Taguchi A; Fukuda T; Miyamoto Y; Tanikawa M; Mori-Uchino M; Tsuruga T; Iriyama T; Matsumoto Y; Nagasaka K; Wada-Hiraike O; Oda K; Hamamoto R; Osuga Y
Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358786
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a selective, substrate-competitive inhibitor of the lysine methyltransferase SETD8.
Ma A; Yu W; Li F; Bleich RM; Herold JM; Butler KV; Norris JL; Korboukh V; Tripathy A; Janzen WP; Arrowsmith CH; Frye SV; Vedadi M; Brown PJ; Jin J
J Med Chem; 2014 Aug; 57(15):6822-33. PubMed ID: 25032507
[TBL] [Abstract][Full Text] [Related]
13. The histone methyltransferase Setd8 acts in concert with c-Myc and is required to maintain skin.
Driskell I; Oda H; Blanco S; Nascimento E; Humphreys P; Frye M
EMBO J; 2012 Feb; 31(3):616-29. PubMed ID: 22117221
[TBL] [Abstract][Full Text] [Related]
14. Novel MDM2 inhibitor SAR405838 (MI-773) induces p53-mediated apoptosis in neuroblastoma.
Lu J; Guan S; Zhao Y; Yu Y; Wang Y; Shi Y; Mao X; Yang KL; Sun W; Xu X; Yi JS; Yang T; Yang J; Nuchtern JG
Oncotarget; 2016 Dec; 7(50):82757-82769. PubMed ID: 27764791
[TBL] [Abstract][Full Text] [Related]
15. Histone methyltransferase Setd8 represses Gata2 expression and regulates erythroid maturation.
Malik J; Getman M; Steiner LA
Mol Cell Biol; 2015 Jun; 35(12):2059-72. PubMed ID: 25848090
[TBL] [Abstract][Full Text] [Related]
16. SETD8 stabilized by USP17 epigenetically activates SREBP1 pathway to drive lipogenesis and oncogenesis of ccRCC.
Li X; Liu Z; Xia C; Yan K; Fang Z; Fan Y
Cancer Lett; 2022 Feb; 527():150-163. PubMed ID: 34942305
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological and transcriptional inhibition of the G9a histone methyltransferase suppresses proliferation and modulates redox homeostasis in human microvascular endothelial cells.
Wojtala M; Macierzyńska-Piotrowska E; Rybaczek D; Pirola L; Balcerczyk A
Pharmacol Res; 2018 Feb; 128():252-263. PubMed ID: 29113759
[TBL] [Abstract][Full Text] [Related]
18. The histone methyltransferase Setd8 alters the chromatin landscape and regulates the expression of key transcription factors during erythroid differentiation.
Myers JA; Couch T; Murphy Z; Malik J; Getman M; Steiner LA
Epigenetics Chromatin; 2020 Mar; 13(1):16. PubMed ID: 32178723
[TBL] [Abstract][Full Text] [Related]
19. A Chromatin-Focused siRNA Screen for Regulators of p53-Dependent Transcription.
Sammons MA; Zhu J; Berger SL
G3 (Bethesda); 2016 Aug; 6(8):2671-8. PubMed ID: 27334938
[TBL] [Abstract][Full Text] [Related]
20. Sensitivity to cdk1-inhibition is modulated by p53 status in preclinical models of embryonal tumors.
Schwermer M; Lee S; Köster J; van Maerken T; Stephan H; Eggert A; Morik K; Schulte JH; Schramm A
Oncotarget; 2015 Jun; 6(17):15425-35. PubMed ID: 26029996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
